search
Back to results

Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

Primary Purpose

Cocaine-Related Disorders, Substance-Related Disorders

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Methylphenidate
Sponsored by
National Institute on Drug Abuse (NIDA)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Cocaine-Related Disorders

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Healthy normals Exclusion Criteria: History of head trauma or loss of consciousness. Significant medical history. History of seizures.

Sites / Locations

  • New York MDRU

Outcomes

Primary Outcome Measures

Dopamine receptor availability

Secondary Outcome Measures

Full Information

First Posted
April 18, 2001
Last Updated
February 23, 2017
Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
New York MDRU
search

1. Study Identification

Unique Protocol Identification Number
NCT00015301
Brief Title
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
Official Title
Methylphenidate Raclopride PET Test
Study Type
Interventional

2. Study Status

Record Verification Date
December 2002
Overall Recruitment Status
Completed
Study Start Date
December 2003 (Actual)
Primary Completion Date
June 2005 (Actual)
Study Completion Date
August 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
New York MDRU

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.
Detailed Description
The objective of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine-Related Disorders, Substance-Related Disorders

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Masking
Double
Enrollment
0 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Methylphenidate
Primary Outcome Measure Information:
Title
Dopamine receptor availability

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Healthy normals Exclusion Criteria: History of head trauma or loss of consciousness. Significant medical history. History of seizures.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John Rotrosen, M.D.
Organizational Affiliation
New York MDRU
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York MDRU
City
New York
State/Province
New York
ZIP/Postal Code
10010
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

We'll reach out to this number within 24 hrs